Objectives: The role of MDR1 in clinical paclitaxel resistance remains poorly characterized. This study sought to identify the incidence and significance of P-glycoprotein (P-gp) over-expression on survival, tumor response to paclitaxel and the effect of prior cytotoxic exposure on P-gp expression in patients with paired primary and recurrent ovarian cancer samples.
Methods: Retrospective survival analysis. P-gp expression was evaluated immunohistochemically with antibodies c494 and c219.
Results: Thirty-two patients were identified from the tumor registry. Median interval between primary and secondary surgery was 17.9 (5.7-40.9) months. Only five primary tumors (16%) demonstrated +++ staining for P-gp. First-line treatment contained paclitaxel in 17 patients (53%) and 26 patients (81%) had been exposed to P-gp exportable chemotherapy before second surgery. Only seven of the recurrent tumors (22%) were +++. Only one of seven (14% (95% CI 0-46%)) recurrent tumors with ++ or +++ staining responded to subsequent paclitaxel, while 8 of 10 (80% (CI 46-100%)) recurrent tumors with 0/+ staining responded (P = 0.025). In multivariate analysis of outcome following second surgery, response to paclitaxel (P = 0.004) and P-gp over-expression (P < 0.001) were significant predictors of survival.
Conclusions: De novo strong P-gp over-expression is uncommon, appears to change little over time or with prior exposure to chemotherapy. However, P-gp over-expression is a significant prognostic factor, and at the time of disease, relapse is inversely correlated with tumor response to paclitaxel.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ygyno.2003.11.053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of in Non-small Cell Lung Cancer.
Anticancer Res
December 2024
Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Background/aim: Chemoresistance to paclitaxel (PTX) significantly ameliorates therapeutic efficacy in patients with non-small cell lung cancer (NSCLC), especially in advanced stages, deteriorating the progression free and overall survival rates. One of the critical mechanisms contributing to drug resistance is the excretion of PTX from target cells via efflux pumps. Ivermectin was developed as a bactericidal agent against parasites; however, it has recently been shown to inhibit the proliferation of human cancer cells.
View Article and Find Full Text PDFDesign, synthesis and biological evaluation of biaryl amide derivatives as modulators of multi-drug resistance.
Eur J Med Chem
January 2025
School of Pharmacy, Fudan University, Shanghai, 201203, China. Electronic address:
Article Synopsis
- - The study highlights the challenge of multi-drug resistance (MDR) in cancer treatment, mainly due to the overexpression of ABC transporters like P-glycoprotein (P-gp), which affects the effectiveness of chemotherapy drugs.
- - Researchers explored the biaryl amide skeleton for potential agents to reverse MDR and identified a compound, D2, that significantly reversed resistance to drugs like paclitaxel and cisplatin in various cancer cell lines.
- - Compound D2 works by binding to P-gp, lowering its expression, and enhancing drug accumulation in cells, showing promise as a solution to combat MDR in cancer treatments.
Expressional Study of Permeability Glycoprotein and Multidrug Resistance Protein 1 in Drug-resistant Mesial Temporal Lobe Epilepsy.
Basic Clin Neurosci
September 2023
Department of Neurosurgery, Institute of Medical Education and Research, Chandigarh, India.
Article Synopsis
- - About 30% of epilepsy patients experience refractory seizures due to a lack of response to anti-epileptic drugs, potentially linked to increased activity of drug-efflux transporters like P-glycoprotein and multidrug-resistance associated protein-1.
- - A study examined the expression of these transporters in hippocampal tissues from 15 epilepsy surgery patients and compared them to tissues from 15 non-epileptic individuals, revealing a significant overexpression in the epilepsy cases.
- - The findings suggest that these transporters may contribute to multi-drug resistance in epilepsy, indicating that targeting them could improve the effectiveness of anti-epileptic drugs by enhancing their availability in the brain.
Overexpression of SCN5A overcomes ABC transporter-mediated multidrug resistance in acute myeloid leukemia through promoting apoptosis.
Expert Rev Hematol
February 2024
Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Background: This study aimed to explore the effect and mechanism of SCN5A overcoming ATP-binding cassette (ABC) transporter-mediated multidrug resistance (MDR) in acute myeloid leukemia (AML) through promoting apoptosis.
Research Design And Methods: The tissues derived from AML patients were divided into Sensitive group and Resistance group according to the presence of drug-resistance. Human AML cell line HL-60 and drug-resistant strain HL-60/ADR were divided into HL-60/ADR-vector group, HL-60/ADR-SCN5A group, HL-60-vector group and HL-60-SCN5A group.
Recent developments of P-glycoprotein inhibitors and its structure-activity relationship (SAR) studies.
Bioorg Chem
February 2024
University College of Pharmacy Raipur, Chhattisgarh Swami Vivekananda Technical University, Newai, Bhilai 491107, Chhattisgarh, India. Electronic address:
Article Synopsis
- * P-gp inhibitors show promise as a therapeutic strategy to combat MDR, with recent research focusing on their pharmacological properties and mechanisms of action to enhance treatment options for resistant cancers.
- * Advancements in drug design and the identification of potent, selective, and low-toxicity P-gp inhibitors are crucial for improving drug discovery and developing novel cancer therapies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!